SB 313 xTZ

Drug Profile

SB 313 xTZ

Alternative Names: SB-313; SB-313-xTZ; Zetakine engineered T-cell therapy - Sangamo

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Sangamo BioSciences
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action T-cell receptor gene stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 06 Jan 2017 Sangamo Biosciences is now called Sangamo Therapeutics
  • 22 Mar 2016 Discontinued - Phase-I for Glioblastoma (Combination therapy, Recurrent, Refractory metastatic disease) in USA (Intracerebral)
  • 08 Jan 2015 Sangamo Biosciences in-licenses nanoparticle technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top